Caffeine as symptomatic treatment for Parkinson disease (Café-PD): A randomized trial
Postuma RB, Anang J, Pelletier A, Joseph L, Moscovich M, Grimes D, Furtado S, Munhoz RP, Appel-Cresswell S, Moro A, Borys A, Hobson D, Lang AE
Neurology · 97 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2017-09-28 · Neurology · vol. 89 · número 17 · págs. 1795–1803
- Editorial
- Lippincott Williams & Wilkins
- Citado
- 135 citas · más que el 99% de estudios similares · 9.3× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 28 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Coffee research and impacts · Parkinson's Disease Mechanisms and Treatments · Adenosine and Purinergic Signaling
- Palabras clave
- Placebo, Tolerability, Montreal Cognitive Assessment, Dyskinesia, Parkinsonism, Rating scale, Medicine, Somnolence, Internal medicine, Physical therapy, Psychology, Parkinson's disease, Adverse effect, Disease, Dementia
- MeSH
- humans, parkinson disease, caffeine, antiparkinson agents, treatment outcome, severity of illness index, follow-up studies, double-blind method, time factors, aged, middle aged, female, male
13 autores
- Ronald B. Postuma🇨🇦🇧🇷🇺🇸University of Ottawa; University of Calgary; Pontifícia Universidade Católica do Paraná; Toronto Western Hospital; Ottawa Hospital; MIND Research Institute; uOttawa Brain and Mind Research Institute; Djavad Mowafaghian Centre for Brain Health; University of Manitoba
- Julius B. M. Anang🇨🇦🇧🇷🇺🇸University of Ottawa; University of Calgary; Pontifícia Universidade Católica do Paraná; Toronto Western Hospital; Ottawa Hospital; MIND Research Institute; uOttawa Brain and Mind Research Institute; Djavad Mowafaghian Centre for Brain Health; University of Manitoba
- Amélie Pelletier🇨🇦🇧🇷🇺🇸University of Ottawa; University of Calgary; Pontifícia Universidade Católica do Paraná; Toronto Western Hospital; Ottawa Hospital; MIND Research Institute; uOttawa Brain and Mind Research Institute; Djavad Mowafaghian Centre for Brain Health; University of Manitoba
- Lawrence Joseph🇨🇦🇧🇷🇺🇸University of Ottawa; University of Calgary; Pontifícia Universidade Católica do Paraná; Toronto Western Hospital; Ottawa Hospital; MIND Research Institute; uOttawa Brain and Mind Research Institute; Djavad Mowafaghian Centre for Brain Health; University of Manitoba
- Mariana Moscovich🇨🇦🇧🇷🇺🇸University of Ottawa; University of Calgary; Pontifícia Universidade Católica do Paraná; Toronto Western Hospital; Ottawa Hospital; MIND Research Institute; uOttawa Brain and Mind Research Institute; Djavad Mowafaghian Centre for Brain Health; University of Manitoba
- David A. Grimes🇨🇦🇧🇷🇺🇸University of Ottawa; University of Calgary; Pontifícia Universidade Católica do Paraná; Toronto Western Hospital; Ottawa Hospital; MIND Research Institute; uOttawa Brain and Mind Research Institute; Djavad Mowafaghian Centre for Brain Health; University of Manitoba
- Sarah Furtado🇨🇦🇺🇸University of Ottawa; University of Calgary; Toronto Western Hospital; Ottawa Hospital; MIND Research Institute; uOttawa Brain and Mind Research Institute; Djavad Mowafaghian Centre for Brain Health
- Renato P. Munhoz🇨🇦🇧🇷🇺🇸University of Ottawa; University of Calgary; Pontifícia Universidade Católica do Paraná; Toronto Western Hospital; Ottawa Hospital; MIND Research Institute; uOttawa Brain and Mind Research Institute; Djavad Mowafaghian Centre for Brain Health; University of Manitoba
- Silke Appel‐Cresswell🇨🇦🇧🇷🇺🇸University of Ottawa; University of Calgary; Pontifícia Universidade Católica do Paraná; Toronto Western Hospital; Ottawa Hospital; MIND Research Institute; uOttawa Brain and Mind Research Institute; Djavad Mowafaghian Centre for Brain Health; University of Manitoba
- Adriana Moro🇨🇦🇧🇷🇺🇸University of Ottawa; University of Calgary; Pontifícia Universidade Católica do Paraná; Toronto Western Hospital; Ottawa Hospital; MIND Research Institute; uOttawa Brain and Mind Research Institute; Djavad Mowafaghian Centre for Brain Health; University of Manitoba
- Andrew Borys🇨🇦🇧🇷🇺🇸University of Ottawa; University of Calgary; Pontifícia Universidade Católica do Paraná; Toronto Western Hospital; Ottawa Hospital; MIND Research Institute; uOttawa Brain and Mind Research Institute; Djavad Mowafaghian Centre for Brain Health; University of Manitoba
- Douglas E. Hobson🇨🇦🇧🇷🇺🇸University of Ottawa; University of Calgary; Pontifícia Universidade Católica do Paraná; Toronto Western Hospital; Ottawa Hospital; MIND Research Institute; uOttawa Brain and Mind Research Institute; Djavad Mowafaghian Centre for Brain Health; University of Manitoba
- Anthony E. Lang🇨🇦🇧🇷🇺🇸University of Ottawa; University of Calgary; Pontifícia Universidade Católica do Paraná; Toronto Western Hospital; Ottawa Hospital; MIND Research Institute; uOttawa Brain and Mind Research Institute; Djavad Mowafaghian Centre for Brain Health; University of Manitoba
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objective
To assess effects of caffeine on Parkinson disease (PD).
Methods
In this multicenter parallel-group controlled trial, patients with PD with 1-8 years disease duration, Hoehn & Yahr stages I-III, on stable symptomatic therapy were randomized to caffeine 200 mg BID vs matching placebo capsules for 6-18 months. The primary research question was whether objective motor scores would differ at 6 months (Movement Disorder Society-sponsored Unified Parkinson's Disease Rating Scale [MDS-UPDRS]-III, Class I evidence). Secondary outcomes included safety and tolerability, motor symptoms (MDS-UPDRS-II), motor fluctuations, sleep, nonmotor symptoms (MDS-UPDRS-I), cognition (Montreal Cognitive Assessment), and quality of life.
Results
Sixty patients received caffeine and 61 placebo. Caffeine was well-tolerated with similar prevalence of side effects as placebo. There was no improvement in motor parkinsonism (the primary outcome) with caffeine treatment compared to placebo (difference between groups -0.48 [95% confidence interval -3.21 to 2.25] points on MDS-UPDRS-III). Similarly, on secondary outcomes, there was no change in motor signs or motor symptoms (MDS-UPDRS-II) at any time point, and no difference on quality of life. There was a slight improvement in somnolence over the first 6 months, which attenuated over time. There was a slight increase in dyskinesia with caffeine (MDS-UPDRS-4.1+4.2 = 0.25 points higher), and caffeine was associated with worse cognitive testing scores (average Montreal Cognitive Assessment = 0.66 [0.01, 1.32] worse than placebo).
Conclusion
Caffeine did not provide clinically important improvement of motor manifestations of PD (Class I evidence). Epidemiologic links between caffeine and lower PD risk do not appear to be explained by symptomatic effects.
Clinicaltrialsgov identifier
NCT01738178.
Classification of evidence
This study provides Class I evidence that for patients with PD, caffeine does not significantly improve motor manifestations.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.